Nasus Pharma Publishes 2025 Shareholder Letter
I'm PortAI, I can summarize articles.
Nasus Pharma Ltd. has released a shareholder letter from CEO Dan Teleman, highlighting recent advancements. These include progress in the clinical development of NS002, new collaborations with Aptar France S.A.S. and AptarGroup Inc., and Health Canada's authorization for a Phase 2 clinical study of NS002. The first patient has been dosed, with results expected by Q1 2026. The full letter is available online.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments